NCT04219280View on ClinicalTrials.gov

Evaluating Treatment of ADHD in Children with Down Syndrome

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 2, 2020

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Down SyndromeADHD
Interventions
DRUG

Quillivant XR

Long-lasting liquid solution of Quillivant XR.

DRUG

Placebo

Liquid solution to mimic the color and taste of Quillivant XR.

Trial Locations (4)

15203

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

45229

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

95817

COMPLETED

University of California Davis MIND Institute, Sacramento

02115

RECRUITING

Boston Children's Hospital, Boston

All Listed Sponsors
collaborator

University of California, Davis

OTHER

collaborator

University of Pittsburgh Medical Center

OTHER

collaborator

Boston Children's Hospital, Boston, MA, USA

OTHER

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT04219280 - Evaluating Treatment of ADHD in Children with Down Syndrome | Biotech Hunter | Biotech Hunter